Establishing quality indicators for point of care glucose testing: recommendations from the Canadian Society for Clinical Chemists Point of Care Testing and Quality Indicators Special Interest Groups.

POCT critical results positive patient ID quality assurance quality indicators risk assessment

Journal

Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306

Informations de publication

Date de publication:
27 06 2023
Historique:
received: 09 02 2023
accepted: 17 03 2023
medline: 30 5 2023
pubmed: 13 4 2023
entrez: 12 4 2023
Statut: epublish

Résumé

Monitoring quality indicators (QIs) is an important part of laboratory quality assurance (QA). Here, the Canadian Society of Clinical Chemists (CSCC) Point of Care Testing (POCT) and QI Special Interest Groups describe a process for establishing and monitoring QIs for POCT glucose testing. Key, error prone steps in the POCT glucose testing process were collaboratively mapped out, followed by risk assessment for each step. Steps with the highest risk and ability to detect a non-conformance were chosen for follow-up. These were positive patient identification (PPID) and repeat of critically high glucose measurements. Participating sites were asked to submit aggregate data for these indicators from their site(s) for a one-month period. The PPID QI was also included as part of a national QI monitoring program for which fifty-seven sites submitted data. The percentage of POCT glucose tests performed without valid PPID ranged from 0-87%. Sites without Admission-Discharge-Transfer (ADT) connectivity to POCT meters were among those with the highest percentage of POCT glucose tests performed without valid PPID. The percentage repeated critically high glucose measurements ranged from 0-50%, indicating low compliance with this recommendation. A high rate of discordance was also noted when critically high POCT glucose measurements were repeated, demonstrating the importance of repeat testing prior to insulin administration. Here, a process for establishing these QIs is described, with preliminary data for two QIs chosen from this process. The findings demonstrate the importance of QIs for identification and comparative performance monitoring of non-conformances to improve POCT quality.

Identifiants

pubmed: 37043622
pii: cclm-2023-0147
doi: 10.1515/cclm-2023-0147
doi:

Substances chimiques

Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1280-1287

Informations de copyright

© 2023 the author(s), published by De Gruyter, Berlin/Boston.

Références

Mainz, J. Defining and classifying clinical indicators for quality improvement. Int J Qual Health Care 2003;15:523–30. https://doi.org/10.1093/intqhc/mzg081 .
doi: 10.1093/intqhc/mzg081
Plebani, M, Astion, ML, Barth, JH, Chen, W, de Oliveira Galoro, CA, Escuer, MI, et al.. Harmonization of quality indicators in laboratory medicine. A primary consensus. Clin Chem Lab Med 2014;52:951–8. https://doi.org/10.1515/cclm-2014-0142 .
doi: 10.1515/cclm-2014-0142
Sciacovelli, L, Padoan, A, Aita, A, Basso, D, Plebani, M. Quality indicators in laboratory medicine: state-of-the-art, quality specifications and future strategies. Clin Chem Lab Med 2023;61:688–95. https://doi.org/10.1515/cclm-2022-1143 .
doi: 10.1515/cclm-2022-1143
ISO 15189:2022. Medical laboratories – requirements for quality and compliance.
Sciacovelli, L, Lippi, G, Sumarac, Z, West, J, del Pino Castro, IG, Furtado Vieira, K, et al.. IFCC Working Group on Laboratory Errors and Patient safety . Quality indicators in laboratory medicine: the status of the progress of IFCC Working Group “laboratory errors and patient safety” project. Clin Chem Lab Med 2017;55:348–57. https://doi.org/10.1515/cclm-2016-0929 .
doi: 10.1515/cclm-2016-0929
Shaw, JL, McCudden, CR, Colantonio, DA, Booth, RA, Lin, DC, Blasutig, IM, et al.. Effective interventions to improve the quality of critically high point-of-care glucose results. Prac Lab Med 2020;22:e00184. https://doi.org/10.1016/j.plabm.2020.e00184 .
doi: 10.1016/j.plabm.2020.e00184
Plebani, M, Sciacovelli, L, Marinova, M, Marcuccitti, J, Chiozza, ML. Quality indicators in laboratory medicine: a fundamental tool for quality and patient safety. Clin Biochem 2013;46:1170–4. https://doi.org/10.1016/j.clinbiochem.2012.11.028 .
doi: 10.1016/j.clinbiochem.2012.11.028
Brun, M, Fuzery, AK, Henschke, B, Rozak, K, Venner, AA. Identifying sources of error and selecting quality indicators for point of care testing. Prac Lab Med 2021;25:200216.
Janssens, PMW. Practical, transparent prospective risk analysis for the clinical laboratory. Ann Clin Biochem 2014;51:695–704. https://doi.org/10.1177/0004563214521160 .
doi: 10.1177/0004563214521160
Societe quebecoise de biologie clinique. 2022. Program for quality indicators comparison. Available from: https://caqbc.sqbc.qc.ca/Homepage=Home [Accessed Aug 2022].
Van Hoof, V, Bench, S, Soto, AB, Luppa, PP, Malpass, A, Schilling, UM, et al.. Failure Mode and Effects Analysis (FMEA) at the preanalytical phase for POCT blood gas analysis: proposal for a shared proactive risk analysis model. Clin Chem Lab Med 2022;60:1186–201. https://doi.org/10.1515/cclm-2022-0319 .
doi: 10.1515/cclm-2022-0319

Auteurs

Julie L V Shaw (JLV)

Division of Biochemistry, Eastern Ontario Regional Laboratories Association and University of Ottawa, Ottawa, ON, Canada.

Saranya Arnoldo (S)

William Osler Health System, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Lori Beach (L)

Pathology and Laboratory Medicine, IWK Health and Dalhousie University, Halifax, NS, Canada.

Ihssan Bouhtiauy (I)

Division of Biochemistry, Vitalite Health Network, Edmundston, NB, Canada.

Davor Brinc (D)

Laboratory Medicine Program, University Health Network, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Miranda Brun (M)

Alberta Precision Laboratories and Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.

Christine Collier (C)

Royal Columbian Hospital and Department of Pathology and Laboratory Medicine, University of British Columbia, Westminster, BC, Canada.

Elie Kostantin (E)

Clinical Department of Laboratory Medicine, Cite-de-la-Sante Hospital, Optilab LLL and University of Montreal, Montreal, QC, Canada.

Angela W S Fung (AWS)

Department of Pathology and Laboratory Medicine, St. Paul's Hospital and University of British Columbia, Vancouver, BC, Canada.

Anna K Füzéry (AK)

Alberta Precision Laboratories and Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.

Yun Huang (Y)

Kingston Health Sciences, Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.

Sukhbir Kaur (S)

Clinical Biochemistry Division, Laboratory Medicine, Saskatchewan Health Authority, Saskatoon, SK, Canada.

Michael Knauer (M)

Pathology and Laboratory Medicine, London Health Sciences and University of Western Ontario, London, ON, Canada.

Lyne Labrecque (L)

Clinical Department of Laboratory Medicine, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada.

Felix Leung (F)

Department of Pathology and Laboratory Medicine, Sinai Health System, Department Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Jennifer L Shea (JL)

Department of Laboratory Medicine, Saint John Regional Hospital, Horizon Health, Department of Pathology, Dalhousie University, St. John, NB, Canada.

Vinita Thakur (V)

Department of Laboratory Medicine, Eastern Health Authority and Memorial University, St. John's, NL, Canada.

Laurel Thorlacius (L)

Clinical Biochemistry, Shared Health and University of Manitoba, Winnipeg, MB, Canada.

Allison A Venner (AA)

Alberta Precision Laboratories and Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.

Paul M Yip (PM)

Precision Diagnostics and Therapeutics Program, Sunnybrook Health Sciences Centre, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Vincent De Guire (V)

Hospital Maisonneuve-Rosemont, Grappe OPTILAB, Montreal CHUM, Montreal, QC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH